Nutr Diabetes
Serious risks may include pancreatitis, gallbladder disease, dehydration, kidney injury, and possible thyroid concerns in selected patients
GBD Chronic Kidney Disease Collaboration
For Medicare Part D, this model will be implemented in January 2027, following a separate short-term demonstration that will allow Medicare Part D enrollees to access obesity drugs beginning in July 2026
However, dedicated kidney outcome trials for GLP-1 receptor agonists remain limited, and further long-term studies are needed to better define their role in CKD management
For most people, that difference is smalland for those who would not otherwise use an injectable medication, a pill may be the more practical choice